How to combine degenerative medicine with regenerative medicine using biologics and cell therapies

How to combine degenerative medicine with regenerative medicine using biologics and cell therapies

Global Summit on Biopharma & Biotherapeutics
May 14-15, 2018 | Montreal, Canada

Michel Mikhail

BioNTech AG, Germany

Scientific Tracks Abstracts : Asian J Biomed Pharmaceut Sci

Abstract:

The breakthrough therapies with immuno-oncology biologics aiming at stimulating the T-lymphocytes targeting the specific tumor after identification of the gene mutation pattern of the tumor using new generation sequencing (NGS), aim at stopping tumor progression in first instance then degenerating the tumor up-to complete dryingoff and disappearance. After the complete degeneration of the tumor achieving a progression-free survival, the corresponding organ can be regenerated using the patient’s own skin- or fat cells, to obtain induced pluripotent stem cells that regenerate the organ, this is in also relevant for visible organs like in case of breast cancer. With the stem cell therapy, deficient organs can be regenerated and human longevity significantly prolonged. Combining degenerative medicine with regenerative medicine is a vision that becomes reality.

Biography:

Michel Mikhail has more than 30 years of pharmaceutical industry experience and track record of achievement in R&D and international regulatory affairs in large multinational research-based pharmaceutical as well as biotech companies. He is a Chartered Expert in Pharmacology-Toxicology, a Chartered Clinical Expert as well as a Chartered Analytical Expert. He has participated in the development of ICH guidelines, served on the Safety Working Group and Efficacy Working Group of the European Federation of Pharmaceutical Industry Associations (EFPIA) also as a Topic Leader. He has served on the Regulatory Group of the European branch of the Pharmaceutical Research and Manufacturers of America (PhRMA Europe). He is a Member of the Expert Committee of the Governmental Federal Institute of Risk Assessment (BfR) Germany and served as Member of the Expert Committee for Toxicology of the United States Pharmacopoeia (USP).
Email: mikhailm2001@aol.com

PDF HTML